1. Home
  2. SLN vs SAMG Comparison

SLN vs SAMG Comparison

Compare SLN & SAMG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • SAMG
  • Stock Information
  • Founded
  • SLN 1994
  • SAMG 2002
  • Country
  • SLN United Kingdom
  • SAMG United States
  • Employees
  • SLN N/A
  • SAMG N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • SAMG Investment Managers
  • Sector
  • SLN Health Care
  • SAMG Finance
  • Exchange
  • SLN Nasdaq
  • SAMG Nasdaq
  • Market Cap
  • SLN 165.3M
  • SAMG 151.4M
  • IPO Year
  • SLN N/A
  • SAMG 2013
  • Fundamental
  • Price
  • SLN $3.70
  • SAMG $14.50
  • Analyst Decision
  • SLN Buy
  • SAMG
  • Analyst Count
  • SLN 5
  • SAMG 0
  • Target Price
  • SLN $32.60
  • SAMG N/A
  • AVG Volume (30 Days)
  • SLN 256.3K
  • SAMG 73.8K
  • Earning Date
  • SLN 05-08-2025
  • SAMG 05-08-2025
  • Dividend Yield
  • SLN N/A
  • SAMG 5.52%
  • EPS Growth
  • SLN N/A
  • SAMG N/A
  • EPS
  • SLN N/A
  • SAMG 0.94
  • Revenue
  • SLN $27,701,000.00
  • SAMG $124,771,000.00
  • Revenue This Year
  • SLN N/A
  • SAMG $9.70
  • Revenue Next Year
  • SLN N/A
  • SAMG $7.28
  • P/E Ratio
  • SLN N/A
  • SAMG $15.42
  • Revenue Growth
  • SLN N/A
  • SAMG 5.51
  • 52 Week Low
  • SLN $1.97
  • SAMG $14.26
  • 52 Week High
  • SLN $24.38
  • SAMG $19.20
  • Technical
  • Relative Strength Index (RSI)
  • SLN 55.23
  • SAMG 35.89
  • Support Level
  • SLN $3.54
  • SAMG $15.50
  • Resistance Level
  • SLN $4.15
  • SAMG $16.23
  • Average True Range (ATR)
  • SLN 0.33
  • SAMG 0.46
  • MACD
  • SLN 0.06
  • SAMG 0.08
  • Stochastic Oscillator
  • SLN 53.62
  • SAMG 35.69

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.

About SAMG Silvercrest Asset Management Group Inc.

Silvercrest Asset Management Group Inc is a wealth management firm focused on providing financial advisory and related family office services to ultra-high net-worth individuals and institutional investors. It advises clients on traditional investment strategies focused on equities, fixed income and cash as well as non-traditional investment strategies including hedge funds, private equity funds, real estate and commodities. It also provides clients with family office services and related administrative services, which include financial planning, tax planning and preparation, partnership accounting and fund administration, and consolidated wealth reporting. The company derives revenues principally from assets under management.

Share on Social Networks: